Baseline characteristics of Ph-like ALL, Ph+ ALL, and B-other ALL
| . | B-ALL categories, N = 155 . | ||||
|---|---|---|---|---|---|
| Ph-like . | Ph+ . | B-other . | P (all 3 groups) . | P (Ph-like vs B-other) . | |
| N | 56 | 46 | 53 | ||
| Age, y median (range) | 33.5 (15-71) | 49 (22-84) | 38 (15-79) | .001 | .23 |
| <40, n (%) | 37 (66) | 18 (39) | 29 (55) | ||
| ≥40, n (%) | 19 (34) | 28 (61) | 24 (45) | ||
| Sex, n (%) | |||||
| Female | 19 (34) | 24 (52) | 34 (64) | .006 | .002 |
| Male | 37 (66) | 22 (48) | 19 (36) | ||
| Ethnicity, n (%) | |||||
| White | 13 (23) | 20 (44) | 27 (51) | ||
| Hispanic | 38 (68) | 16 (35) | 16 (30) | <.001 | <.001 |
| African American | 2 (4) | 8 (17) | 6 (11) | ||
| Asian | 3 (5) | 2 (4) | 2 (4) | ||
| Unclassified | — | — | 2 (4) | ||
| Cytogenetics, n = 142, n (%) | <.001 | .002 | |||
| Diploid | 19 (39) | — | 11 (23) | ||
| Hyperdiploid | 10 (20) | — | 8 (17) | ||
| Hypodiploid | 4 (8) | — | 3 (7) | ||
| Miscellaneous | 16 (33) | — | 11 (23) | ||
| MLL | — | — | 14 (30) | ||
| Ph+ | — | 46 (100) | — | ||
| Presenting features | |||||
| WBC, ×109/L, median (range) | 17 (1-603) | 13 (0-165) | 6 (1-670) | .18 | .14 |
| Platelet count, ×109/L, median (range) | 37 (1-238) | 43 (4-273) | 41 (7-513) | .43 | .31 |
| Hemoglobin, g/dL, median (range) | 9.3 (5.7-15.1) | 10 (6-12.8) | 9 (4.8-13.8) | .11 | .10 |
| Bone marrow blast %, median (range) | 90 (17-99) | 89 (44-98) | 88 (28-97) | .87 | .59 |
| CNS involvement at Dx, n (%) | 8 (14) | 8 (17) | 6 (11) | .69 | .65 |
| Treatment received, n (%) | |||||
| Hyper-CVAD based | 37 (66) | 46 (100) | 41 (77) | <.001 | .19 |
| Augmented BFM | 19 (34) | — | 12 (23) | ||
| . | B-ALL categories, N = 155 . | ||||
|---|---|---|---|---|---|
| Ph-like . | Ph+ . | B-other . | P (all 3 groups) . | P (Ph-like vs B-other) . | |
| N | 56 | 46 | 53 | ||
| Age, y median (range) | 33.5 (15-71) | 49 (22-84) | 38 (15-79) | .001 | .23 |
| <40, n (%) | 37 (66) | 18 (39) | 29 (55) | ||
| ≥40, n (%) | 19 (34) | 28 (61) | 24 (45) | ||
| Sex, n (%) | |||||
| Female | 19 (34) | 24 (52) | 34 (64) | .006 | .002 |
| Male | 37 (66) | 22 (48) | 19 (36) | ||
| Ethnicity, n (%) | |||||
| White | 13 (23) | 20 (44) | 27 (51) | ||
| Hispanic | 38 (68) | 16 (35) | 16 (30) | <.001 | <.001 |
| African American | 2 (4) | 8 (17) | 6 (11) | ||
| Asian | 3 (5) | 2 (4) | 2 (4) | ||
| Unclassified | — | — | 2 (4) | ||
| Cytogenetics, n = 142, n (%) | <.001 | .002 | |||
| Diploid | 19 (39) | — | 11 (23) | ||
| Hyperdiploid | 10 (20) | — | 8 (17) | ||
| Hypodiploid | 4 (8) | — | 3 (7) | ||
| Miscellaneous | 16 (33) | — | 11 (23) | ||
| MLL | — | — | 14 (30) | ||
| Ph+ | — | 46 (100) | — | ||
| Presenting features | |||||
| WBC, ×109/L, median (range) | 17 (1-603) | 13 (0-165) | 6 (1-670) | .18 | .14 |
| Platelet count, ×109/L, median (range) | 37 (1-238) | 43 (4-273) | 41 (7-513) | .43 | .31 |
| Hemoglobin, g/dL, median (range) | 9.3 (5.7-15.1) | 10 (6-12.8) | 9 (4.8-13.8) | .11 | .10 |
| Bone marrow blast %, median (range) | 90 (17-99) | 89 (44-98) | 88 (28-97) | .87 | .59 |
| CNS involvement at Dx, n (%) | 8 (14) | 8 (17) | 6 (11) | .69 | .65 |
| Treatment received, n (%) | |||||
| Hyper-CVAD based | 37 (66) | 46 (100) | 41 (77) | <.001 | .19 |
| Augmented BFM | 19 (34) | — | 12 (23) | ||
Dx, diagnosis.